Table 2. Odds of Mortality Univariate and Multivariate Analysis

| Variable | Odds Ratio (Confidence Interval) | P-value |
|-------------------------|-------------------------------------|----------|
| Univariate Analysis | | |
| Age | 1.032 (1.007-1.058) | 0.0133 |
| ICU | 10.239 (5.48-19.133) | <0.001 |
| Intubated | 12.406 (6.854-22.456) | <0.0001 |
| CKD History | 2.891 (1.749-4.778) | < 0.0001 |
| mSOFA score | 1.405 (1.264-1.562) | <0.0001 |
| Central Venous Catheter | 3.285 (1.737-6.212) | 0.0003 |
| BSI | 2.890 (1.832-4.559) | <0.0001 |
| Multivariate Analysis | | |
| Age | 1.070 (1.058-1.083) | <0.0001 |
| mSOFA | 1.285 (1.125-1.468) | <0.0001 |
| ICU stay | 7.908 (5.752-10.871) | < 0.0001 |
| BSI | 1.686 (0.986-2.884) | 0.0564 |



Conclusion: Although more than half of hospitalized COVID-19 pts had BC done, the number of BSI were low suggesting overutilization of BC. BSI was associated with older age and disease severity. Mortality was not affected by BSI but was primarily driven by age and severity of illness.

Disclosures: Indira Brar, MD, Gilead (Speaker's Bureau)janssen (Speaker's Bureau)ViiV (Speaker's Bureau) Marcus Zervos, MD, Melinta Therapeutics (Grant/ Research Support)

408. Evaluation of the negative predictive value of the SARS-CoV-2 PCR respiratory assays in asymptomatic children undergoing surgery

Suchitra Rao, MDLilliam Ambroggio, PhD, MPH¹; Edwin J. Asturias, MD²; Lalit Bajaj, MD,MPH/MSPH²; Michelle Corrado, MD, MBA²; Thomas Inge, MD, PhD²; Sarah Jung, PhD³; Tyler Morrissey, MD²; Christina M. Osborne, MD⁴; Justin B. Searns, MD⁵; Gina Whitney, MD²; Samuel Dominguez, MD, PhD⁶; ¹Children's Hospital Colorado, Denver, CO; ²University of Colorado School of Medicine, Aurora, Colorado; ³Children's Hospital Colorado, Aurora, Colorado; ⁴Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, Colorado; ⁵Children's Hospital Colorado, University of Colorado, Aurora, CO; ⁶University of Colorado, School of Medicine, San Francisco, California

Session: P-13. COVID-19 Diagnostics

Background: Universal pre-operative screening with SARS-CoV-2 PCR has been adopted by institutions to mitigate risk to healthcare workers (HCW) during aerosol-generating procedures such as intubation. However, there remains uncertainty regarding rates of false negative results and optimal sampling type. The objective was to determine the reliability of single, pre-operative SARS-CoV-2 testing from the naso-pharynx in children undergoing general anesthesia.

Methods: Children < 18 years of age who underwent intubation for a procedure received pre-operative testing 24-48 hours prior with a nasopharyngeal (NP) swab or wash, in conjunction with intra-operative nasal wash (NW) and tracheal aspirate (TA) sampling. All paired samples underwent testing using the Simplexa DiaSorin platform or a modified Centers for Disease Control assay. Cohen's Kappa was used for interrater reliability of each sample result. McNemar's Test was used to compare result proportions by sample type. Positive and negative predictive values (PPV, NPV) were calculated based on the intraoperative NW as the reference standard. Analyses were conducted using SAS (v 9.4).

Results: We collected full sample sets from 364 children from April 14 to May 15; 66% of pre-operative samples were NP swabs. The median age was 6 years (IQR 2,13), 55% were male, 68% were white and 41% of children had a high-risk comorbidity. Most surgeries were conducted by general surgery (23%), followed by orthopedics (19%). Only 2.5% of children had respiratory symptoms, and 4.8% had a documented fever within a week of the procedure. SARS-CoV-2 positive samples occurred in 4/364 (1%) of pre-operative samples, 8/363 (2.2%) of intra-operative samples, and 8/348 (2.3%)

of TA samples. The pre-operative test had 100% PPV and 99% NPV, and the TA had 100% PPV and 98.6% NPV (Table 1). There was very good agreement (Figure) between pre- and intraoperative upper respiratory sampling, with a Kappa of 0.66, (95% CI 0.35–0.97). There was no statistical difference in results by sample type.

Table 1. Comparison of intra-operative and pre-operative nasopharyngeal sample results, test characteristics and test concordance

| | | Intra-operative nasopharyngeal wash | | |
|---|----------|-------------------------------------|----------|-------|
| | | Positive | Negative | Total |
| Pre-operative Positive nasopharyngeal swab/wash Negative Total | Positive | 4 | 0 | 4 |
| | Negative | 4 | 355 | 359 |
| | | | | |
| | Total | 8 | 355 | 363 |

Kappa 0.66 (95%Cl 0.35-0.97)

Sensitivity 50% (95%Cl 16-84%) Specificity 100% (95%Cl 99-100%)

Positive Predictive Value 100% (95%CI 40-100%)

Negative Predictive Value 99% (95% CI 97-100%)

Table 2. Comparison of intra-operative nasopharyngeal and tracheal aspirate sample results, test characteristics and test concordance

| | | Intra-operative tracheal aspirate | | |
|--|----------|-----------------------------------|----------|-------|
| | | Positive | Negative | Total |
| Intra-operative Positive nasopharyngeal wash Negative Total | Positive | 3 | 5 | 8 |
| | Negative | 0 | 340 | 340 |
| | Total | 3 | 345 | 348 |

Kappa 0.54 (95%CI 0.18-0.90)

Positive Predictive Value 100 (95%Cl 29-100%)

Negative Predictive Value 100 (95% CI 29-100%) Negative Predictive Value 98.6% (95% CI 97-100%)

NPW



Conclusion: There is a high PPV and NPV of pre-operative SARS-CoV-2 PCR testing among children undergoing anesthesia. These data can help inform guide-lines regarding appropriate precautions for HCW performing high risk procedures in asymptomatic pediatric patients.

TA

Pre-op

NP/NW

Disclosures: Suchitra Rao, MD, BioFire (Grant/Research Support) Samuel Dominguez, MD, PhD, BioFire (Consultant, Research Grant or Support)

409. Rapid Development of a Multiplexed PCR Prototype Method that Offers a Syndromic Diagnostic Option by Integrating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Detection with Twenty-One Other Common Respiratory Pathogens

Usha Spaulding, PhD¹; Jeremiah Antosch, BS¹; Jessica stone, BS¹; Tanner Robinson, MS¹; Kerrin Halo, BS¹; Iryna Kavetska, BS¹; Tyler Healy, BS¹; Alex Taylor, BS¹; Matthew Jones, MS¹; Toma Todorov, BS¹; Zhenmei Lu, MS¹; Joann Cloud, PhD¹; Maggie Buccambuso, MS¹; Brad Graham, MS¹; Jeremy Boone, BS²; Hillary Wood, PhD²; Margarita Rogatcheva, PhD¹; ¹BioFire Diagnostics, LLC, Salt Lake City, UT; ²MRIGlobal, Kansas City, Missouri

Sensitivity 37.5% (95%Cl 9-76%) Specificity 100% (95%Cl 99-100%)